SequelSEC

VITASPRING BIOMEDICAL CO. LTD. VSBC

Services-Commercial Physical & Biological Research · CIK 0001697884 · Fiscal year ends 0131

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-07-31
Operating income
-$161.82K
Fiscal year ended 2026-07-31
Free cash flow
Unavailable
Fiscal year ended 2026-07-31

Valuation, from the filing

Public float$3.09KMarket value of stock held by non-affiliates, as stated on the cover page for 2022-04-27
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2022-04-27, not today.

How this compares in its industry

Percentile among the Services-Commercial Physical & Biological Research filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio0.00x0th

VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported revenue of $0 and net income of -$155.82K for the fiscal year ended 2026-07-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from VITASPRING BIOMEDICAL CO. LTD.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Commercial Physical & Biological Research.

Income

VITASPRING BIOMEDICAL CO. LTD. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$161.82K-$75.84K-$81.46K-$135.73K-$99.07K-$69.15K-$126.49K-$117.93K-$218.66K-$216.83K
Net income-$155.82K-$75.84K-$81.46K-$142.52K-$110.84K-$80.54K-$143.14K-$196.29K-$218.66K-$216.83K
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 207.03Mshares 207.03MUnavailableshares 207.03Mshares 207.03Mshares 207.03MUnavailableshares 207.03Mshares 207.03Mshares 207.03M
Pretax income-$155.82K-$75.84K-$81.46K-$135.73K-$99.07K-$69.15K-$126.49K-$117.93K-$218.66K-$216.83K
Income tax expense$0$0$0$6.78K$11.78K$11.39K$16.64K$78.36K$0$0
Diluted EPS$0.00$0.00Unavailable$0.00$0.00$0.00Unavailable$0.00$0.00$0.00
Selling, general & administrative$5.83K$75.84K$81.46K$135.73K$6.05K$69.15K$126.49K$117.93K$218.66K$216.83K
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

VITASPRING BIOMEDICAL CO. LTD. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Cash & equivalentsUnavailableUnavailableUnavailable$0$0$0$0$2.06KUnavailableUnavailable
Total assets$14.82K$11.43K$14.68K$16.46K$17.02K$11.91K$14.38K$58.38K$64.33K$131.29K
Current assets$14.82K$9.77K$10.53K$9.83K$7.89K$295$272$41.79K$45.25K$64.31K
Total liabilities$4.68M$4.52M$4.45M$4.37M$4.22M$4.11M$4.03M$3.93M$3.77MUnavailable
Current liabilities$2.27M$4.52M$4.45M$4.37M$4.22M$4.11M$4.03M$3.93M$3.77M$3.66M
Total equity incl. NCI-$4.66M-$4.51M-$4.43M-$4.35M-$4.21M-$4.10M-$4.02M-$3.87M-$3.70M-$3.53M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$0
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$0Unavailable$2.41M$2.41M$2.41M$2.41M$2.41M$2.41M$2.41M$2.41M

Cash flow

VITASPRING BIOMEDICAL CO. LTD. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Operating cash flow$5.20K$6.08K$124-$839-$1.19K-$787-$1.79K-$6.44K-$2.42K-$4.02K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$0$0$0$2.00K$1.98K$515$0$2.98K$6.98K$4.98K
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensationUnavailableUnavailable$0$0$0$0$0$27.48K$41.22K$41.22K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailable$2.49KUnavailable$2.49K$2.49K$2.49K$2.49K$2.49K$2.49K$2.49K

Derived

VITASPRING BIOMEDICAL CO. LTD. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-07-312026-04-302026-01-312025-10-312025-07-312025-04-302025-01-312024-10-312024-07-312024-04-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.01x0.00x0.00x0.00x0.00x0.00x0.00x0.01x0.01x0.02x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VSBC in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-09-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-K · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-17View SEC filing
10-Q · Filed 2026-06-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.